Immunization of high-risk infants younger than 18 months of age with split-product influenza vaccine
JR Groothuis, G Meiklejohn, BA Lauer, MJ Levin… - …, 1991 - publications.aap.org
Influenza is an important cause of serious illness in very young children with
cardiopulmonary disease. A 4-year study was conducted at two centers to assess
immunogenicity and safety of influenza split-product vaccine in children aged 3 to 18 months
with bronchopulmonary dysplasia and congenital heart disease. A total of 113 children were
studied: 62 children 3 to 5 months of age and 51 children 6 to 18 months of age. Sera were
drawn prior to first and second immunization and 3 weeks after second immunization and …
cardiopulmonary disease. A 4-year study was conducted at two centers to assess
immunogenicity and safety of influenza split-product vaccine in children aged 3 to 18 months
with bronchopulmonary dysplasia and congenital heart disease. A total of 113 children were
studied: 62 children 3 to 5 months of age and 51 children 6 to 18 months of age. Sera were
drawn prior to first and second immunization and 3 weeks after second immunization and …